Innovent Biologics' (HKG:1801) new drug application for arcotatug tavatecan was accepted by China's National Medical Products Administration and granted priority review, according to a Thursday Hong Kong bourse filing.
The application was submitted after an international multi-center phase 3 clinical study of the drug reached the primary endpoint after completing the per-protocol first interim analysis.
The drug demonstrated excellent efficacy and a tolerable safety profile in the treatment of advanced gastric cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments